Natco Pharma

The drug major filed an abbreviated new drug application (ANDA) for generic versions of Olaparib tablets - 100 mg and 150 mg with the US Food and Drug Administration (USFDA)

May open floodgates for Indian drugmakers to launch the generic version of the drug as early as next week

CLOSING BELL: Besides, the Nifty Auto and Private Bank indices advanced 1.7 per cent each

Stocks to Watch Today: Oil related shares are likely to be in focus on Tuesday as the oil ministry sought a review of the windfall profit tax on domestically produced crude oil.

Stocks to Watch: Blackstone Inc. is seeking to raise as much as Rs 3,180 crore ($400 million) through the sale of shares in Indian automotive component maker Sona Comstar

CLOSING BELL: The winners included Indian Oil Corporation, Sun Pharma, Tata Consumer Products, TCS, Cipla, Shree Cement, NTPC, Tech M, Dr Reddy's Labs, Wipro, Ultratech Cement, and Infosys

Logistics stocks have been showing strength on the medium term charts, according to Vinay Rajani of HDFC Securities.

The company's board has approved to acquire Dash Pharmaceuticals through one of its subsidiary units, it said

Natco Pharma on Thursday said it has launched a novel fixed-dose combination of Trifluridine and Tipiracil, used to treat advanced colorectal and gastric cancer, in the country. The company has launched the product under the brand name Tipanat in a pack of 20 tablets in a bottle, Natco Pharma said in a regulatory filing. Tipanat is a novel antineoplastic nucleoside analog indicated for the treatment of advanced colorectal and gastric cancer. In India, around 1,25,000 new cases of the above-mentioned cancers are reported every year. Tipanat is of high importance in not only extending survival but also in preserving the quality of life in the late lines of treatment which is currently an unmet medical need, the drug maker said. The company said it has launched the medication at an affordable price.

Dr Reddy's Laboratories and Natco Pharma on Thursday said they have launched generic capsules used in the treatment of multiple myeloma and myelodysplastic syndrome patients in the Canadian market.

The Hon'ble High Court of Delhi today orally pronounced judgment in the interim injunction application filed by FMC Corporation on CTPR

The company has received approval from the US health regulator for the generic version of Celgene's multiple myeloma drug, Revlimid (Lenalidomide) capsules in the US

Natco Pharma has received emergency use approval for Baricitinib tablets, for the treatment of Covid-19 positive patients, from the Central Drugs Standard Control Organization (CDSCO) in India

The company has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India

Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of Covid-19 replication

Natco Pharma Limited on Monday said it applied to the Central Drugs Standard Control Organisation (CDSCO) for approval of Phase-III clinical trial of Molnupiravir Capsules

Drug major Natco Pharma on Friday said its board has approved acquiring about 1 per cent stake in its Canadian subsidiary

Consolidated total income of the company stood at Rs 827.9 crore for the quarter under consideration

Strong impetus to exports by a mega product launch in North America and business outside the US bode well for earnings

Natco Pharma aims to launch around 10 new products every year in the Indian market, the city-based drug maker said on Thursday